Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Gains from Investment Securities (2024 - 2026)

Evommune (EVMN) reported Gains from Investment Securities of $100000.0 for Q1 2026, down 74.68% on a QoQ basis from $395000.0 in Q4 2025.

Evommune (EVMN) has 3 years of Gains from Investment Securities data on file, last reported at $100000.0 in Q1 2026.

  • Quarterly Gains from Investment Securities changed N/A year-over-year to $100000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $401000.0 (changed N/A YoY) and the FY2025 annual result came in at $6.6 million, up 1382.88% from the prior year.
  • Gains from Investment Securities fell to $100000.0 in Q1 2026 per EVMN's latest filing, from $395000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $395000.0 in Q4 2025 and bottomed at -$94000.0 in Q4 2024.
  • The 3-year median for Gains from Investment Securities is $57361.5 (2025), against an average of $103930.8.
  • Peak annual rise in Gains from Investment Securities reached 520.21% in 2025, while the deepest fall reached 520.21% in 2025.
  • Tracing EVMN's Gains from Investment Securities over 3 years: stood at -$94000.0 in 2024, then surged by 520.21% to $395000.0 in 2025, then slumped by 74.68% to $100000.0 in 2026.
  • Per Business Quant, the three latest EVMN Gains from Investment Securities figures stand at $100000.0 (Q1 2026), $395000.0 (Q4 2025), and $14723.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Evommune 744.11 Mn 532.65 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 100,000.00
Mar 31, 2026 100,000.00
Dec 31, 2025 395,000.00
Dec 31, 2025 395,000.00
Sep 30, 2025 14,723.00
Sep 30, 2025 14,723.00
Dec 31, 2024 -94,000.00
Dec 31, 2024 -94,000.00